Predicting clinical outcome in CLL: how and why
Open Access
- 1 January 2009
- journal article
- review article
- Published by American Society of Hematology in Hematology
- Vol. 2009 (1), 421-429
- https://doi.org/10.1182/asheducation-2009.1.421
Abstract
The clinical course of patients with chronic lymphocytic leukemia (CLL) is heterogeneous, with some patients experiencing rapid disease progression and others living for decades without requiring treatment. Clinical features and molecular/biologic factors such as ZAP-70, immunoglobulin heavy chain (IGHV) gene mutation status, and cytogenetic abnormalities on fluorescent in situ hybridization (FISH) have been found to be robust predictors of treatment-free survival and overall survival among newly diagnosed patients. Beyond their widely recognized value for providing insight into disease biology and utility for stratifying patient risk in clinical trials, these prognostic tools play an important role in the current counseling and management of patients with CLL. Recent studies have focused on how to combine the results of multiple prognostic assays into an integrated risk stratification system and explored how these characteristics influence response to treatment. This chapter reviews the available tools to stratify patient risk and discusses how these tools can be used in routine clinical practice to individualize patient counseling, guide the frequency of follow-up, and inform treatment selection.Keywords
This publication has 54 references indexed in Scilit:
- Brief Report: Natural History of Individuals With Clinically Recognized Monoclonal B-Cell Lymphocytosis Compared With Patients With Rai 0 Chronic Lymphocytic LeukemiaJournal of Clinical Oncology, 2009
- Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemiaBlood, 2009
- The physician–patient relationship and quality of life: Lessons from chronic lymphocytic leukemiaLeukemia Research, 2009
- Validation of a new prognostic index for patients with chronic lymphocytic leukemiaCancer, 2009
- Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative ConditioningJournal of Clinical Oncology, 2008
- Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemiaBlood, 2008
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute–Working Group 1996 guidelinesBlood, 2008
- Cancer Statistics, 2008CA: A Cancer Journal for Clinicians, 2008
- Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemiaBlood, 2006
- Prediction of Survival in Diffuse Large-B-Cell Lymphoma Based on the Expression of Six GenesNew England Journal of Medicine, 2004